Top Suppliers:I want be here




375815-87-5

375815-87-5 structure
375815-87-5 structure
  • Name: Varenicline Tartrate
  • Chemical Name: varenicline tartrate
  • CAS Number: 375815-87-5
  • Molecular Formula: C17H19N3O6
  • Molecular Weight: 361.35
  • Catalog: Biochemical Inhibitor Neuronal Signaling AChR agonist
  • Create Date: 2018-06-20 23:03:29
  • Modify Date: 2024-01-02 18:18:16
  • Varenicline Tartrate(CP 526555;Champix) is a nicotinic receptor partial agonist; it stimulates nicotine receptors more weakly than nicotine itself does.IC50 value:Target: α4β2 nAChRVarenicline(CP 526555; Champix; Chantix) is a prescription medication used to treat smoking addiction. As a partial agonist it both reduces cravings for and decreases the pleasurable effects of cigarettes and other tobacco products. Through these mechanisms Varenicline(CP 526555; Champix; Chantix) can assist some patients to quit smoking.

Name varenicline tartrate
Synonyms 7,8,9,10-Tetrahydro-6,10-methano-6H-pyrazino[2,3-h][3]benzazepine tartrate Champix
(2R,3R)-3-carboxy-2,3-dihydroxypropanoate de (1R,12S)-5,8-diaza-14-azoniatétracyclo[10.3.1.0.0]hexadéca-2(11),3,5,7,9-pentaène
Chantix
(1R,12S)-5,8-Diaza-14-azoniatetracyclo[10.3.1.0.0]hexadeca-2(11),3,5,7,9-pentaene (2R,3R)-3-carboxy-2,3-dihydroxypropanoate
(1R,12S)-5,8-Diaza-14-azoniatetracyclo[10.3.1.0.0]hexadeca-2(11),3,5,7,9-pentaen-(2R,3R)-3-carboxy-2,3-dihydroxypropanoat
Butanedioic acid, 2,3-dihydroxy-, (2R,3R)-, compd. with (6R,10S)-7,8,9,10-tetrahydro-6,10-methano-6H-azepino[4,5-g]quinoxaline (1:1)
Champix
Varenicline tartrate
Description Varenicline Tartrate(CP 526555;Champix) is a nicotinic receptor partial agonist; it stimulates nicotine receptors more weakly than nicotine itself does.IC50 value:Target: α4β2 nAChRVarenicline(CP 526555; Champix; Chantix) is a prescription medication used to treat smoking addiction. As a partial agonist it both reduces cravings for and decreases the pleasurable effects of cigarettes and other tobacco products. Through these mechanisms Varenicline(CP 526555; Champix; Chantix) can assist some patients to quit smoking.
Related Catalog
References

[1]. Krebs P, Sherman SE. Review: Varenicline for tobacco cessation does not increase CV serious adverse events. Ann Intern Med. 2012 Aug 21;157(4):JC2-2.

[2]. Kikkawa, H.; Maruyama, N.; Fujimoto, Y.; Hasunuma, T. Single- and multiple-dose pharmacokinetics of the selective nicotinic receptor partial agonist, varenicline, in healthy Japanese adult smokers. Journal of Clinical Pharmacology (2011), 51(4), 527-537.

[3]. Pachas GN, Cather C, Pratt SA et al. Varenicline for Smoking Cessation in Schizophrenia: Safety and Effectiveness in a 12-Week, Open-Label Trial. J Dual Diagn. 2012;8(2):117-125.

[4]. Bordia T, Hrachova M, Chin M et al. Varenicline Is a Potent Partial Agonist at α6β2* Nicotinic Acetylcholine Receptors in Rat and Monkey Striatum. J Pharmacol Exp Ther. 2012 Aug;342(2):327-34.

[5]. Varenicline

Boiling Point 400.6ºC at 760 mmHg
Melting Point 206-208ºC
Molecular Formula C17H19N3O6
Molecular Weight 361.35
PSA 23.79000
LogP 4.49528
Storage condition Desiccate at RT
Water Solubility DMSO: >5mg/mL
Symbol GHS02 GHS06 GHS08
GHS02, GHS06, GHS08
Signal Word Danger
Hazard Statements H225-H301 + H311 + H331-H370
Precautionary Statements P210-P260-P280-P301 + P310-P311
Hazard Codes Xn,N,T,F
Risk Phrases 22-50-39/23/24/25-23/24/25-11
Safety Phrases 22-57-45-36/37-16-7
RIDADR UN 3077 9 / PGIII
Flash Point(F) 48.2 °F
Flash Point(C) 9 °C

~64%

375815-87-5 structure

375815-87-5

Literature: Medichem, S.A. Patent: US2012/4239 A1, 2012 ; Location in patent: Page/Page column 12 ;
Precursor  2

DownStream  0